# Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

> **NCT03519230** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 224 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Pamiparib capsule
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT03519230
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-14
- **Primary completion:** 2025-12-01
- **Final completion:** 2027-01-30
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03519230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03519230, "Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03519230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*